Compare CREX & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CREX | PDSB |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.5M | 40.0M |
| IPO Year | 2015 | 2015 |
| Metric | CREX | PDSB |
|---|---|---|
| Price | $3.11 | $0.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 27.1K | ★ 248.7K |
| Earning Date | 04-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 2.86 | ★ 28.16 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,437,000.00 | N/A |
| Revenue This Year | $81.98 | N/A |
| Revenue Next Year | $14.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.61 | N/A |
| 52 Week Low | $2.19 | $0.51 |
| 52 Week High | $4.42 | $1.55 |
| Indicator | CREX | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 34.98 | 40.72 |
| Support Level | $2.67 | $0.70 |
| Resistance Level | $3.09 | $0.76 |
| Average True Range (ATR) | 0.16 | 0.04 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 1.49 | 47.87 |
Creative Realities Inc, along with its subsidiaries, is engaged in providing digital marketing technology & solutions to world-wide retail companies, luxury and other individual retail brands, advertising networks, outdoor clients, enterprises, and other organizations. The company operates in one reportable segment, marketing technology solutions. It offers solutions related to digital merchandising systems, omnichannel customer engagement systems, interactive digital shopping assistants, advisors and kiosks, and high-end audio-visual networks, along with marketing technologies such as mobile, social media, point-of-sale transactions, beaconing, and web-based media. Geographically, the company generates maximum revenue from the United States, and the rest from Canada.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.